GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ligand Pharmaceuticals Inc (NAS:LGND) » Definitions » Beneish M-Score

Ligand Pharmaceuticals (Ligand Pharmaceuticals) Beneish M-Score

: -2.24 (As of Today)
View and export this data going back to 1995. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.24 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Ligand Pharmaceuticals's Beneish M-Score or its related term are showing as below:

LGND' s Beneish M-Score Range Over the Past 10 Years
Min: -4.37   Med: -2.33   Max: -0.49
Current: -2.24

During the past 13 years, the highest Beneish M-Score of Ligand Pharmaceuticals was -0.49. The lowest was -4.37. And the median was -2.33.


Ligand Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for Ligand Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ligand Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.12 -1.53 -1.84 -4.37 -2.24

Ligand Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.37 -3.91 -4.01 -3.82 -2.24

Competitive Comparison

For the Biotechnology subindustry, Ligand Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ligand Pharmaceuticals Beneish M-Score Distribution

For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Ligand Pharmaceuticals's Beneish M-Score falls into.



Ligand Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Ligand Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.6768+0.528 * 0.7944+0.404 * 1.078+0.892 * 0.6691+0.115 * 1.1094
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.126+4.679 * -0.056156-0.327 * 0.2
=-2.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $39.3 Mil.
Revenue was 28.101 + 32.868 + 26.366 + 43.979 = $131.3 Mil.
Gross Profit was 26.46 + 29.383 + 24.697 + 40.262 = $120.8 Mil.
Total Current Assets was $237.4 Mil.
Total Assets was $787.2 Mil.
Property, Plant and Equipment(Net PPE) was $25.1 Mil.
Depreciation, Depletion and Amortization(DDA) was $35.6 Mil.
Selling, General, & Admin. Expense(SGA) was $52.8 Mil.
Total Current Liabilities was $16.8 Mil.
Long-Term Debt & Capital Lease Obligation was $5.8 Mil.
Net Income was 18.188 + -10.273 + 2.29 + 41.949 = $52.2 Mil.
Non Operating Income was 18.893 + -15.363 + 3.118 + 40.136 = $46.8 Mil.
Cash Flow from Operations was 8.065 + 7.646 + -0.082 + 33.948 = $49.6 Mil.
Total Receivables was $35.0 Mil.
Revenue was 50.382 + 59.221 + 50.126 + 36.516 = $196.2 Mil.
Gross Profit was 28.768 + 45.068 + 37.765 + 31.817 = $143.4 Mil.
Total Current Assets was $263.6 Mil.
Total Assets was $762.7 Mil.
Property, Plant and Equipment(Net PPE) was $27.5 Mil.
Depreciation, Depletion and Amortization(DDA) was $51.4 Mil.
Selling, General, & Admin. Expense(SGA) was $70.1 Mil.
Total Current Liabilities was $98.8 Mil.
Long-Term Debt & Capital Lease Obligation was $10.3 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(39.312 / 131.314) / (35.038 / 196.245)
=0.299374 / 0.178542
=1.6768

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(143.418 / 196.245) / (120.802 / 131.314)
=0.730811 / 0.919948
=0.7944

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (237.429 + 25.062) / 787.216) / (1 - (263.601 + 27.491) / 762.668)
=0.666558 / 0.618324
=1.078

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=131.314 / 196.245
=0.6691

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(51.37 / (51.37 + 27.491)) / (35.643 / (35.643 + 25.062))
=0.651399 / 0.587151
=1.1094

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(52.79 / 131.314) / (70.062 / 196.245)
=0.402013 / 0.357013
=1.126

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((5.755 + 16.782) / 787.216) / ((10.336 + 98.81) / 762.668)
=0.028629 / 0.143111
=0.2

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(52.154 - 46.784 - 49.577) / 787.216
=-0.056156

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Ligand Pharmaceuticals has a M-score of -2.24 suggests that the company is unlikely to be a manipulator.


Ligand Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Ligand Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Ligand Pharmaceuticals (Ligand Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA, USA, 92121
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Executives
Martine Zimmermann director C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BOULEVARD SUITE 110, SAN DIEGO CA 92121
Todd C Davis director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Andrew Reardon officer: CHIEF LEGAL OFFICER & C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Octavio Espinoza officer: Chief Financial Officer C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 110, SAN DIEGO CA 92121
John W Kozarich director 10275 SCIENCE CENTER DR, SAN DIEGO CA 92121
Stephen L Sabba director DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791
John L Higgins officer: CEO & President 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jason Haas director C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Matthew W Foehr officer: EVP and COO 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
John L Lamattina director 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Jennifer R. Cochran director C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Charles S Berkman officer: Asso. Gen. Counsel, Secretary 11085 NORTH TORREY PINES ROAD, SUITE 300, LA JOLLA CA 92037
Sunil Patel director 11085 NORTH TORREY PINES RD., SUITE 300, LA JOLLA CA 92037
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282

Ligand Pharmaceuticals (Ligand Pharmaceuticals) Headlines

From GuruFocus

Ligand to Report First Quarter 2023 Financial Results on May 4, 2023

By Business Wire Business Wire 04-24-2023

Ligand to Report Fourth Quarter Financial Results on February 22

By Business Wire Business Wire 02-06-2023